Alector (ALEC) Preferred Stock Liabilities (2018)
Alector (ALEC) reported Preferred Stock Liabilities of $210.5 million for Q4 2018, little changed quarter-over-quarter from $210.2 million in Q3 2018.
Alector (ALEC) Preferred Stock Liabilities (2018) Analysis & Trends
Alector (ALEC) has 1 years of Preferred Stock Liabilities data on file, last reported at $210.5 million in Q4 2018.
- Preferred Stock Liabilities for Q4 2018 came in at $210.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was $210.5 million (changed N/A YoY), and the FY2018 annual result was $210.5 million, up 171.69% from the prior year.
- Preferred Stock Liabilities steadied at $210.5 million in Q4 2018 per ALEC's latest filing, from $210.2 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $210.5 million in Q4 2018 and troughed at $77.5 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alector | 193.53 Mn | -12.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 210.52 Mn |
| Sep 30, 2018 | 210.17 Mn |
| Jun 30, 2018 | 147.57 Mn |
| Mar 31, 2018 | 77.49 Mn |